|
|
Post by trenddiver on Oct 20, 2014 19:42:53 GMT -5
Since the Board represents so many shares, it would be smart if we posed some questions to Management on the next conference call which is scheduled in a week or two. Someone from the Board should present the one or two of the most important questions that are reached by Board consensus. I suggest the Board Administrators make a determine who will present our questions.
Here is my suggestion for a question to management:
Does the Company have any information, plan or strategy regarding the huge short interest position and does the Company have any information regarding alleged naked shorting of the Mannkind's stock including the many failure to deliver conditions that have existed over the past several months? Has Mannkind contacted or been contacted by the SEC regarding this?
Trend
|
|
|
|
Post by gwb on Oct 20, 2014 20:02:46 GMT -5
Hey Trend , that's a great place to start , I know more about the hookers the secret service banged out in Cartagena Columbia than I do MNKD. I have been a shareholder over 7 seven years and I am frustrated with the silence and not being given any information . I would think MNKD has the "right" for discovery of information pertaining to these shortsellers . We may suggest a formal PR dept be setup, hell any of us could perform that function.
|
|
|
|
Post by jpg on Oct 21, 2014 0:12:14 GMT -5
That would be an amazing question.
JPG
|
|
|
|
Post by bighaus89 on Oct 21, 2014 10:04:38 GMT -5
That is probably the best and most relevant question right now in our favorite hit drama, Mannkind.
|
|
|
|
Post by liane on Oct 21, 2014 10:29:42 GMT -5
I'm not aware that we, as mere mortals, can ask questions on the cc.
|
|
|
|
Post by babaoriley on Oct 21, 2014 12:34:41 GMT -5
You're no mere mortal, liane, I think you should call and register yourself as a potential questioner. And if they ask you what you are interested in, make sure you tell them you want to delve into the short interest, and I'm sure they'll put you right at the top of the list!! Unfortunately, your connection will somehow fail, just at the critical time.
|
|
|
|
Post by purge on Oct 21, 2014 19:36:10 GMT -5
I mean we all should represent enough shares that we should get our questions answered.
How can we find out what we have to do get two or three questions answered?
|
|
|
|
Post by dt on Oct 23, 2014 5:18:43 GMT -5
Matt makes himself very accessible. Why don't we send a few questions to him now, with the caveat that we understand that he might not be able to answer yet , but that we would appreciate it if these questions could be answered during the next cc.
Hopefully he will either confirm that he will consider the questions or at least reply that the questions will still not be answerable during the cc (in which case at least we will set our expectations more appropriately).
I will add a line of questioning for consideration:
Matt earlier mentioned that the B/S and P&L would look totally different, based on how the accounting for the deal came through. In fact I believe he stated that at that point he still didn't know what the outcome would be, but that it would all be cleared up on the next earnings announcement. It seems basic to me that he will expect to have to go into detail, but in my experience companies tend to try to keep some wiggle room in the level of detail they present. This is not just MNKD - it is everybody. For example, Matt gave a comparison of the 35% profit share is similar to a 'mid-20s' royalty. Will he go into the detail of the factors in the equation that make up the difference (ie cost of goods sold, etc)? I doubt it. And I wouldn't really blame him or think less of MNKD. With this in mind, my question(s):
1) As sales ramp, what factors might improve the gross profitability of the venture? Will certain fixed costs be amortized/averaged against a larger revenue base? Will certain components become cheaper at volume production?
2) Also I would like a clarification/confirmation that the $925m of payments from Sanofy to MNKD DO NOT get factored into the gross profitability of the venture. For example, the 150m already paid should not mean the venture starts off with a loss of 150m built into the profit share calc. A numerical example (I am making up these numbers): if $250m is due to MNKD when sales hit $1b, and at $1b there is $700m of gross profits, I would expect MNKD to be paid:
MNKD return:
700m x 35% = 245m
PLUS
250m
Total => 495m
Which would mean that to that point Sanofy's overall return will look like:
700m x 65% = 455
MINUS
400m (payments of 150m and 250m)
Total => 55m
3) What, if any, previous costs (ie, R&D and/or Danbury facility setup and/or stored insulin if used) will be run through the venture, and therefore effectively reimbursed to the MNKD? And if reimbursed, talk through how this will flow through P&L (if already expensed).
Best dt
|
|
|
|
Post by dreamboatcruise on Oct 23, 2014 5:27:45 GMT -5
What would be the earliest and latest time that MNKD would anticipate adding more fill lines to manufacturing?
|
|
|
|
Post by otherottawaguy on Oct 23, 2014 9:16:09 GMT -5
Here's hoping that some of the 150M milestone is going to be used to add production lines, but I have been saying this since the last Deerfield tranche of 40M being equivalent of at least 4 additional lines.
I have asked Matt twice about this via email with no response about expanded production, but have since read on one of the boards that he responded to another's question on the subject that this would give away Sanofi's potential marketing numbers and that it would need to remain as undisclosed.
OOG
|
|
|
|
Post by babaoriley on Oct 23, 2014 9:51:51 GMT -5
I'd still like to know if they plan to launch sales in the first quarter, or if Sanofi's waiting until they get their new insulin approved. Let's hope that Sanofi will be at least marketing to those who haven't taken insulin yet, but should be.
|
|
|
|
Post by mannmade on Oct 23, 2014 10:16:25 GMT -5
Baba, my understanding is that they still plan on a mid 1st Q 2015 launch as of right now.
|
|
|
|
Post by mnkdorbust on Oct 23, 2014 10:19:50 GMT -5
Here's hoping that some of the 150M milestone is going to be used to add production lines, but I have been saying this since the last Deerfield tranche of 40M being equivalent of at least 4 additional lines. I have asked Matt twice about this via email with no response about expanded production, but have since read on one of the boards that he responded to another's question on the subject that this would give away Sanofi's potential marketing numbers and that it would need to remain as undisclosed. OOG I agree. I hope there is more on the lines going on behind the scenes that we don't know about. Since i feel we don't know about much at all there is likely a good chance but just my "hopes/opinion". In the grand scheme of things they are relative inexpensive considering once A is on the market if it ends up like the elmo christmas toy (everyone wants it and only a few can get it) a few years back it will be bad. I mean it's a good and bad problem. Good that everyone wants it and bad because they can't get it which is a loss for patients and shareholders. Also looking ahead assuming Technosphere is used for other drugs more lines are definitely needed. What are the full details of the ex exubra plant that SNY owns (as far as i know they purchased from Pfizer) in Europe? Has it been in use since it was purchased? What happens there? Possible extension of Technosphere production down the road? |
|
|
|
Post by dreamboatcruise on Oct 23, 2014 11:02:47 GMT -5
We clearly need a spy in the Danbury plant. A chameleon would be a good choice to blend in... but I've got a day job. |
|
|
|
Post by brentie on Oct 23, 2014 11:13:43 GMT -5
|
|
